Evidence map›Paper›PMID 32967729›Full record

ArticleStem cell research & therapy2020

Human amniotic epithelial cells ameliorate kidney damage in ischemia-reperfusion mouse model of acute kidney injury.

Yifei Ren, Ying Chen, Xizi Zheng, Hui Wang, Xin Kang, Jiawei Tang, Lei Qu, Xiaoyan Shao, Suxia Wang, Shuangling Li and 2 more

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. The therapeutic potential of exosomes in lung cancer.Cellular oncology (Dordrecht, Netherlands) · 2023
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Yifei RenRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, 100034, People's Republic of China.
Ying ChenRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, 100034, People's Republic of China.
Xizi ZhengRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, 100034, People's Republic of China.
Hui WangRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, 100034, People's Republic of China.
Xin KangRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, 100034, People's Republic of China.
Jiawei TangRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, 100034, People's Republic of China.
Lei QuRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, 100034, People's Republic of China.
Xiaoyan ShaoShanghai iCELL Biotechnology Co Ltd., Shanghai, 200333, People's Republic of China.
Suxia WangRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, 100034, People's Republic of China.
Shuangling LiDepartment of Critical Care Medicine, Peking University First Hospital, Beijing, 100034, People's Republic of China.
Gang LiuRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, 100034, People's Republic of China.
Li YangRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, 100034, People's Republic of China. li.yang@bjmu.edu.cn.ORCID 0000-0002-2528-5087
Peking University · CNShanghai CASB Biotechnology (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute kidney injury (AKI) is a common clinical disease with complex pathophysiology and limited therapeutic choices. This prompts the need for novel therapy targeting multiple aspects of this disease. Human amnion epithelial cell (hAEC) is an ideal stem cell source. Increasing evidence suggests that exosomes may act as critical cell-cell communicators. Accordingly, we assessed the therapeutic potential of hAECs and their derived exosomes (hAECs-EXO) in ischemia reperfusion mouse model of AKI and explored the underlying mechanisms.

methodsThe hAECs were primary cultured, and hAECs-EXO were isolated and characterized. An ischemic-reperfusion injury-induced AKI (IRI-AKI) mouse model was established to mimic clinical ischemic kidney injury with different disease severity. Mouse blood creatinine level was used to assess renal function, and kidney specimens were processed to detect cell proliferation, apoptosis, and capillary density. Macrophage infiltration was analyzed by flow cytometry. hAEC-derived exosomes (hAECs-EXO) were used to treat hypoxia-reoxygenation (H/R) injured HK-2 cells and mouse bone marrow-derived macrophages to evaluate their protective effect in vitro. Furthermore, hAECs-EXO were subjected to liquid chromatography-tandem mass spectrometry for proteomic profiling.

resultsWe found that systematically administered hAECs could improve mortality and renal function in IRI-AKI mice, decrease the number of apoptotic cells, prevent peritubular capillary loss, and modulate kidney local immune response. However, hAECs showed very low kidney tissue integration. Exosomes isolated from hAECs recapitulated the renal protective effects of their source cells. In vitro, hAECs-EXO protected HK-2 cells from H/R injury-induced apoptosis and promoted bone marrow-derived macrophage polarization toward M2 phenotype. Proteomic analysis on hAECs-EXO revealed proteins involved in extracellular matrix organization, growth factor signaling pathways, cytokine production, and immunomodulation. These findings demonstrated that paracrine of exosomes might be the key mechanism of hAECs in alleviating renal ischemia reperfusion injury.

conclusionsWe reported hAECs could improve survival and ameliorate renal injury in mice with IRI-AKI. The anti-apoptotic, pro-angiogenetic, and immunomodulatory capabilities of hAECs are at least partially, through paracrine pathways. hAECs-EXO might be a promising clinical therapeutic tool, overcoming the weaknesses and risks associated with the use of native stem cells, for patients with AKI.

Indexed as

Acute Kidney InjuryReperfusion InjuryAmnionAnimalsEpithelial CellsHumansIschemiaKidneyMiceProteomicsReperfusionAcute kidney injuryCell therapyExosomeHuman amnion epithelial cellsIschemia

Identifiers

PMID32967729
PMCPMC7510147
OpenAlexW3088047634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.